Navigation Links
Cytos Biotechnology Reports Results from Phase IIa Study with,CYT003-QbG10 in Patients Suffering from Atopic Dermatitis

SCHLIEREN (Zurich), Switzerland, July 3, 2007 - Cytos Biotechnology AG (SWX:CYTN) announced today results from a phase IIa study with CYT003-QbG10 in atopic dermatitis. CYT003-QbG10 is an immunotherapeutic product candidate currently in development for the treatment of allergic diseases. The present study aimed to assess safety, tolerability and exploratory efficacy of the product candidate in a new indication, namely atopic dermatitis. The study was designed as a placebo-controlled, randomized and double-blind trial in 36 patients suffering from mild to moderate atopic dermatitis (AD). Exploratory efficacy was determined according to the Eczema Area and Severity Index (EASI), a commonly applied test to assess the extent and severity of AD.

Treatment with CYT003-QbG10 was safe and generally well tolerated. In both the placebo-treated and CYT003-QbG10-treated groups a similar reduction of the EASI scores was measured over the study period indicating no treatment effect for CYT003-QbG10 in atopic dermatitis at the dose level tested in this trial.

Dr. Wolfgang Renner, CEO of Cytos Biotechnology, commented: “While CYT003-QbG10 has shown strong efficacy in conjunction with a specific allergen in patients with house dust mite allergy, we are still in the process of identifying the best treatment parameters for its application as a monotherapy. This monotherapy has achieved first promising results in grass pollen and also house dust mite allergy. For the latter indication we are now testing higher doses of the product candidate. Based on the outcome of these studies we will then also consider the path forward in atopic dermatitis.”

About the phase IIa study
The randomized, double-blind and placebo-controlled phase IIa study included 36 male and female patients aged 18 to 65 and suffering from mild to moderate AD. Upon entry into the study, the extent and severity of the disease was assessed by the Eczema Area Severit
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Cytos Reports Results from Phase I/IIa Study with CYT007-TNFQb for the Treatment of Psoriasis
2. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
3. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
4. Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease
5. Prana Biotechnology Presents New Key Findings on PBT2
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ASCO Annual Meeting
7. Generex Biotechnology Vaccine Strategy Presented at International Conference in London
8. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at AUA Annual Meeting
9. Cougar Biotechnology Presents Positive CB7630 Clinical Data at AACR Annual Meeting Late-Breaking Clinical Trials Session
10. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
11. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
Post Your Comments:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)... YORK , May 22, 2015  The ... of Zarxio (filgrastim-sndz) -- the first biosimilar product ... -- points toward growth in the contract ... The mainstream CMO industry is geared to the ... to produce major biopharmaceutical products. The healthcare market ...
(Date:5/22/2015)... May 22, 2015  The Mesothelioma Victims Center ... of mesothelioma get the best possible compensation, and they ... with this rare cancer caused by exposure to ... information related to treatment options such as a ... the Mesothelioma Victims Center anytime at 866-714-6466. ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 2Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 3Kalorama: First FDA-Approved Biosimilar Brings Hope for CMO Growth 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 2Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 3Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 4Mesothelioma Victims Center Calls Attention to a Recent Medical Article About a New Drug That Could Slow the Progression of Mesothelioma and Allow People to Live Longer 5
... Company Focused on IND-Enabling Work with Protein Therapeutics that ... Modulate Alternative Pathway of Complement System, CAMBRIDGE, ... has initiated a corporate growth plan with the,appointment of ... of its headquarters in Cambridge, Mass. Dr. Celniker succeeds,Woodruff ...
... Nonin Medical, a leading innovator,of physiological monitoring solutions ... testing phase with its breakthrough technology to measure,regional ... is the continuous monitoring of the regional blood ... testing data and outcomes from an ongoing clinical ...
Cached Medicine Technology:Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 2Taligen Therapeutics Initiates Corporate Growth Plan with Appointment of Abbie Celniker, Ph.D., as CEO and Establishment of Cambridge, Mass., Headquarters 3Nonin Medical Inc. Announces Entry Into the Cerebral Oximeter Market 2
(Date:5/26/2015)... 26, 2015 Writers and editors ... the Vasont® CCMS to make creating, editing, and ... top component content management system (CCMS) software provider, ... supports oXygen XML Editor Version 17.0, Syncro Soft’s ... Integrator extension merges key editorial functionality of the ...
(Date:5/26/2015)... The European imaging IT market will grow ... healthcare providers plan to make purchases. , Over 240 ... collected from these participants show that speech recognition is a ... seat. , “Many imaging IT vendors are poised to ... Jeremy Bikman. “This report details the European market in ways ...
(Date:5/26/2015)... 26, 2015 The Brain Aneurysm Foundation ... Pops and their renowned Conductor Keith Lockhart will once ... evening, June 10, 2015—the 4th Annual Brain Aneurysm ... Pops Night is set to feature an exclusive Brain ... Keith Lockhart who tragically lost his sister-in-law to a ...
(Date:5/25/2015)... TX (PRWEB) May 26, 2015 ... 2015” provides comprehensive information on the therapeutic development ... by identifying new targets and MOAs to produce ... 2015 pipeline review of Liver Failure with 22 ... 65 pages is available at http://www.rnrmarketresearch.com/liver-failure-pipeline-review-h1-2015-market-report.html ...
(Date:5/25/2015)... City, NY (PRWEB) May 26, 2015 ... (NAPW) honors Dr. Heather Stanley-Christian ... of the Year Circle. She is recognized with ... is the nation's leading networking organization exclusively for ... over 200 operating local chapters. , "I'm pleased ...
Breaking Medicine News(10 mins):Health News:Vasont Systems Certifies the Integration between the Vasont® Component Content Management System and oXygen® XML Editor 17.0 2Health News:peer60 report: European Healthcare IT Imaging Purchases: 2015 2Health News:Boston Pops & Renowned Conductor Keith Lockhart to Join the Brain Aneurysm Foundation for the 4th Annual Brain Aneurysm Foundation Night at the Pops 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 2Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 3Health News:Liver Failure Pipeline Assessment and Key Players Review H1 2015 Market Research Report Available at RnRMarketResearch.com 4Health News:NAPW Inducts Dr. Heather Stanley-Christian, Systems Chair/Maternal Fetal Medicine at Stroger Hospital, into Its VIP Professional Woman of the Year Circle 2
... New Courses Improve Patient Care and Address State ... (Health Care Compliance,Strategies, Inc.), the leading provider of ... partnership with University,HealthSystem Consortium (UHC) to deliver a ... of 11 courses with multimedia content and,healthcare specific ...
... Irvine Department of Emergency Medicine is hosting the 11th ... 28-29 in Costa Mesa, Calif. As part of the ... findings on a variety of related areas ranging from ... the success of computerized alcohol-use counseling. , ...
... HARRISBURG, Pa., March 26 Governor Edward G.,Rendell today ... Pennsylvanians to begin planning ahead to better meet their ... not something that can be put off. If,people do ... expensive,consequences," Governor Rendell said. "The ,Own Your Future, campaign,empowers ...
... London and Hospital for Sick Kids purchase Open Access ... ... Open Biosystems, Inc.,announced today that two leading research institutions, University ... Canada, have,recently purchased access to Open Biosystems, shRNAmir technologies for,RNAi ...
... of pediatric liver transplant recipients report lower health-related ... after the surgery, compared to reports from the ... dysfunction fall within the normal range. These findings ... Transplantation. The article is also available online at ...
... 26 Target Data Research (TDR),President R.J. Slutz announced ... Forward fund raising campaign which will be held at ... support Step,N Forward and the Office of Public,Guardianship, Advanced ... quality of life and develop strategies to raise the ...
Cached Medicine News:Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 2Health News:HCCS Partners With UHC to Deliver Cultural Competency Courses 3Health News:UC Irvine researchers present latest findings at emergency medicine forum 2Health News:Governor Rendell Announces 'Own Your Future' Campaign; Urges Consumers to Better Plan Their Long-Term Care Needs 2Health News:Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide 2Health News:Open Biosystems' Open Access RNAi Program Continues to Gain Momentum Worldwide 3Health News:Study shows lifetime effects of pediatric liver transplants 2
Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
Medicine Products: